International journal of pediatric otorhinolaryngology · 2025
Bonebridge active transcutaneous bone conduction hearing implant: Results in the pediatric population.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cavallé Garrido Laura, de Paula Vernetta Carlos, Guzmán Calvete Abel, Álvarez Arocas Javier, Gonçalves Cláudia, Armengot Carceller Miguel
Аннотация
PURPOSE: This study provides prospective and retrospective data on safety and performance results with the Bonebridge BCI 602 (MED-EL) active transcutaneous bone conduction implant in children.
METHODS: Audiological data were collected at 3 intervals (preoperative, initial activation and 3 months postoperative). Quality of life was assessed with the Speech, Spatial, and Qualities of Hearing (SSQ12/P), KID KINDL and Audio Processor Satisfaction Questionnaire (APSQ) as well as a postoperative questionnaire specifically designed for this study.
RESULTS: 22 pediatric patients (20 conductive/mixed hearing loss (CHL/MHL) and 2 single-sided deafness (SSD)) aged 4-17 received a BCI 602. Three-month post-op pure-tone average (PTA4) functional gain (FG) was 31.9 dB HL for the CHL/MHL group and 11.3 dB HL in the SSD patients. CHL/MHL patients had a mean word recognition score (WRS) improvement of 80.6 ± 23.9 % at initial activation and 83 ± 20.3 % at 3 months post-op. Speech recognition in noise at +5 dB SNR in the CHL/MHL group improved from 24.6 ± 28.3 % unaided to 74.9 ± 26 % aided at 3 months post-op. The mean post-op total scores were 5.5 ± 1.8 on the SSQ12/P and 8.87 ± 0.93 on the APSQ questionnaires. No major complications were noted on the postoperative questionnaire; minor complications were resolved by the end of the study. Stable bone and air conduction thresholds confirmed device safety.
CONCLUSION: The Bonebridge BCI 602 is safe and effective for use in the pediatric population.
METHODS: Audiological data were collected at 3 intervals (preoperative, initial activation and 3 months postoperative). Quality of life was assessed with the Speech, Spatial, and Qualities of Hearing (SSQ12/P), KID KINDL and Audio Processor Satisfaction Questionnaire (APSQ) as well as a postoperative questionnaire specifically designed for this study.
RESULTS: 22 pediatric patients (20 conductive/mixed hearing loss (CHL/MHL) and 2 single-sided deafness (SSD)) aged 4-17 received a BCI 602. Three-month post-op pure-tone average (PTA4) functional gain (FG) was 31.9 dB HL for the CHL/MHL group and 11.3 dB HL in the SSD patients. CHL/MHL patients had a mean word recognition score (WRS) improvement of 80.6 ± 23.9 % at initial activation and 83 ± 20.3 % at 3 months post-op. Speech recognition in noise at +5 dB SNR in the CHL/MHL group improved from 24.6 ± 28.3 % unaided to 74.9 ± 26 % aided at 3 months post-op. The mean post-op total scores were 5.5 ± 1.8 on the SSQ12/P and 8.87 ± 0.93 on the APSQ questionnaires. No major complications were noted on the postoperative questionnaire; minor complications were resolved by the end of the study. Stable bone and air conduction thresholds confirmed device safety.
CONCLUSION: The Bonebridge BCI 602 is safe and effective for use in the pediatric population.
Предметные рубрики MeSH
HumansChildBone ConductionMaleFemaleChild, PreschoolRetrospective StudiesHearing AidsHearing Loss, ConductiveAdolescentProspective StudiesTreatment OutcomeQuality of LifeSurveys and QuestionnairesAudiometry, Pure-ToneSpeech PerceptionHearing Loss, Mixed Conductive-SensorineuralPatient SatisfactionProsthesis DesignHearing Loss, UnilateralFollow-Up Studies